Program

Program Monday, May 18, 2015

7:15 AM - 8:15 AM
EDUCATIONAL SYMPOSIA
7:15 AM - 8:15 AM
Room: Grand Ballroom, Salon H (Level 5)
DOES REAL WORLD EVIDENCE, IN THE GUISE OF PATIENT REGISTRIES, ADD ANY VALUE TO THE DECISION-MAKING PROCESS?

(Sponsored by ICON)

8:30 AM - 10:30 AM
WELCOME & FIRST PLENARY SESSION
8:30 AM - 8:40 AM
Room: Grand Ballroom, Salon A-F (Level 5)
WELCOME & PRESIDENTIAL ADDRESS
Adrian Towse, MA, MPhil bio
2014-2015 ISPOR President and Director, Office of Health Economics, London, UK
8:40 AM - 8:50 AM
Room: Grand Ballroom, Salon A-F (Level 5)
MEETING PROGRAM OVERVIEW
Lou Garrison, PhD bio
Program Committee Co-Chair and Professor, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA
Penny Mohr, MA bio
Program Committee Co-Chair and Senior Program Officer, Improving Healthcare Systems, Patient-Centered Outcomes Research Institute (PCORI), Washington, DC, USA
8:50 AM - 9:00 AM
Room: Grand Ballroom, Salon A-F (Level 5)
ISPOR 20TH ANNIVERSARY CELEBRATION
A presentation to commemorate ISPOR's history and achievements.
9:00 AM - 10:30 AM
Room: Grand Ballroom, Salon A-F (Level 5)
FIRST PLENARY SESSION: TAKING STOCK OF THE LEARNING HEALTH CARE SYSTEM: WHAT HAVE WE ACHIEVED AND WHY DOES IT MATTER?
Nearly a decade ago, leaders envisioned a pathway to a learning health care system, where research is closely integrated and rapidly translated into practice by making use of electronic data that can track patients across health care providers and time. Since then, there has been substantial public and private investment to make this vision a reality. This session critically examines how far we have come and what the implications are for comparative effectiveness researchers, payers, patients, and the life sciences industry.
Moderator: Penny Mohr, MA bio
Senior Program Officer, Improving Healthcare Systems, Patient-Centered Outcomes Research Institute (PCORI), Washington, DC, USA
Toward a True Learning Health System: How Can We Build Both the Will and the Skill?
Speaker: Sarah Greene, MPH bio
Associate Director, CER Methods and Infrastructure, Patient-Centered Outcomes Research Institute (PCORI), Washington, DC, USA
Health Care Transformation and the Learning Health System: Where Are We and What’s Next?
Speaker: Lewis G. Sandy, MD, FACP bio
Senior Vice President, Clinical Advancement, UnitedHealth Group, Minneapolis, MN, USA
The Learning Health System: An Optimist's Perspective
Speaker: Sachin H. Jain, MD, MBA bio
Chief Medical Officer, CareMore/Anthem and Lecturer in Health Care Policy, Harvard Medical School, Cerritos, CA, USA
8:30 AM - 2:15 PM
RESEARCH POSTER PRESENTATIONS - SESSION I
10:30 AM - 11:00 AM
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I
11:00 AM - 12:00 PM
ISSUE PANELS - SESSION I
Health Policy Development Using Outcomes Research Issues
11:00 AM - 12:00 PM
Room: Grand Ballroom, Salon A, B, F (Level 5)

IP1: SHOULD THE NAME OF THE GAME BE MORE “SKIN IN THE GAME”? THE SCOPE & CONSEQUENCES OF RX COST SHIFTING FROM PAYERS TO PATIENTS (Invited Issue Panel)

Moderator:

Gerry Oster, PhD, Senior Economist, Policy Analysis Inc. (PAI) and Managing Co-Director, MINERVA Health Economics Network, Brookline, MA, USA bio

Panelists:

Elizabeth Hargrave, MPA, Principal Research Scientist, NORC, Bethesda, MD, USA bio

Elise Gould, PhD, Senior Economist & Director of Health Policy Research, Economic Policy Institute, Washington, DC, USA bio

A. Mark Fendrick, MD, Director, University of Michigan, Center for Value-Based Insurance Design, Ann Arbor, MI, USA bio


11:00 AM - 12:00 PM
Room: Grand Ballroom, Salon G (Level 5)

IP2: CAN WE AFFORD MEDICAL BREAKTHROUGHS FOR LARGE PREVALENCE DISEASES? LESSONS FROM HEPATITIS C

Moderator:

Dana P. Goldman, PhD, Leonard D. Schaeffer Chair & Director, Schaeffer Center for Health Policy & Economics, University of Southern California, Los Angeles, CA, USA

Panelists:

Ross Maclean, MD, Chief Operating Officer, Precision Health Economics, Los Angeles, CA, USA

Tomas J. Philipson, PhD, Daniel Levin Professor of Public Policy Studies, Irving B. Harris Graduate School of Public Policy Studies, University of Chicago, Chicago, IL, USA

Adrian Towse, MA, MPhil, Director, Office of Health Economics (OHE), London, UK bio

Use of Real World Data Issues
11:00 AM - 12:00 PM
Room: Grand Ballroom, Salon K-L (Level 5)

IP3: CHALLENGES AND OPPORTUNITIES FOR PRAGMATIC CLINICAL TRIALS – SHOULD EUROPE AND THE UNITED STATES APPROACH THEM DIFFERENTLY?

Moderator:

Rafael Alfonso-Cristancho, MD, PhD, MSc, Director, Value Evidence Analytics, Research and Development, GlaxoSmithKline (GSK), King of Prussia, PA, USA

Panelists:

Bryan R Luce, PhD, Chief Science Officer, Patient-Centered Outcomes Research Institute (PCORI), Washington, DC, USA

Tjeerd Van Staa, MD, PhD, MSc, Professor, Farr Institute, University of Manchester, Manchester, UK

Economic Outcomes Research Issues
11:00 AM - 12:00 PM
Room: Grand Ballroom, Salon H (Level 5)

IP4: WHAT IS THE VALUE OF BIG DATA IN COMPARATIVE EFFECTIVENESS RESEARCH AND CLINICAL DECISION MAKING?

Moderator:

William H. Crown, PhD, Chief Scientific Officer, Optum Labs, Cambridge, MA, USA

Panelists:

Miguel Hernan, MD, DrPH, Professor of Epidemiology and Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA, USA

Sarah Greene, MPH, Associate Director, CER Methods and Infrastructure Program, Patient-Centered Outcomes Research Institute (PCORI), Washington, DC, USA bio

Milton C Weinstein, PhD, Henry J. Kaiser Professor of Health Policy and Management, Harvard T. H. Chan School of Public Health, Boston, MA, USA

Patient-Reported Outcomes & Patient Preference Research Issues
11:00 AM - 12:00 PM
Room: Grand Ballroom, Salon C, D, E (Level 5)

IP5: PROS AND BEYOND: ARE THEY FIT FOR PURPOSE TO IMPROVE HEALTH CARE POLICY AND PRACTICE?

Moderator:

Corinna Sorenson, MPH, MHSA, PhD, Senior Manager, Avalere Health, Washington, DC, USA

Panelists:

Eleanor M Perfetto, PhD, MS, Professor, Pharmaceutical Health Services Research, University of Maryland, School of Pharmacy, Baltimore, MD, USA

Kristi Mitchell, MPH, Senior Vice President, Avalere Health, Washington, DC, USA

Sachin Kamal-Bahl, PhD, Vice President & Head, Global Health & Value Innovation Center, Pfizer, Philadelphia, PA, USA

12:00 PM - 2:15 PM
LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I
12:15 PM - 1:15 PM
EDUCATIONAL SYMPOSIA
12:15 PM - 1:15 PM
Room: Grand Ballroom, Salon C, D, E (Level 5)
EQ-5D-5L: DEVELOPMENT OF THE FIRST NATIONAL TARIFFS

(Sponsored by EuroQol Research Foundation)

12:15 PM - 1:15 PM
ISPOR STUDENT RESEARCH SHOWCASE
Room: Grand Ballroom, Salon J (Level 5)

INTEGRATING BIG DATA, PATIENT DATA, AND COST-EFFECTIVENESS INTO CLINICAL PRACTICE

This session will feature four outcomes research studies conducted by ISPOR student members and presented at the ISPOR 20th Annual International Meeting. A brief summary of the research study and conclusions will be presented by each student author.

Moderators: Dennis Raisch, PhD, Professor, University of New Mexico, College of Pharmacy, Albuquerque, NM, USA; Ebere Onukwugha, MS, PhD, University of Maryland Baltimore, School of Pharmacy, Baltimore, MD, USA; Zeba M. Khan, PhD, RPh, Vice President, Celgene Corporation, Summit, NJ, USA

Speakers: Vardhaman Patel, MS, University of Illinois at Chicago, Chicago, IL, USA; Ruchitbhai M Shah, MS, University of Mississippi, University, MS, USA; Jana Bartakova, MSc, Charles University in Prague, Prague, Czech Republic; Xiao (Angeline) Cheng, PharmD, MSc, City University London, London, UK

12:15 PM - 1:15 PM
ISPOR PERSONALIZED/PRECISION MEDICINE SPECIAL INTEREST GROUP OPEN MEETING
Room: Grand Ballroom, Salon K-L (Level 5)
All ISPOR members interested or working in the area of personalized medicine are welcome to attend the ISPOR Personalized Medicine Special Interest Group meeting. This meeting will provide an opportunity for participants to discuss issues and challenges within this field and develop projects to address them
1:15 PM - 2:15 PM
POSTER AUTHOR DISCUSSION HOUR - SESSION I
2:15 PM - 3:15 PM
RESEARCH PODIUM PRESENTATIONS - SESSION I

2:15 PM - 3:15 PM
Room: Grand Ballroom, Salon G (Level 5)
CV: CARDIOVASCULAR DISEASE RESEARCH STUDIES

CV1

2:15 PM - 2:30 PM

LIFETIME HEALTH CARE COSTS OF OBESITY-RELATED COMORBIDITIES IN THE UNITED STATES, 2007-2010

Chang S, Leung MY, Carlsson NP, Colditz GA
Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, St. Louis, MO, USA

CV2

2:30 PM - 2:45 PM

THE ASSOCIATION BETWEEN ADHERENCE TO CARDIOVASCULAR MEDICATIONS AND HEALTH CARE UTILIZATION

Simon-Tuval T1, Triki N2, Chodick G3, Greenberg D1
1Ben-Gurion University of the Negev, Beer-Sheva, Israel, 2Maccabi Healthcare Services, Tel-Aviv, Israel, 3Maccabi Healthcare Services and Tel-Aviv University, Tel-Aviv, Israel

CV3

2:45 PM - 3:00 PM

PREVALENCE AND DIRECT MEDICAL COSTS ASSOCIATED WITH ANGINA AND CHEST PAIN FOLLOWING PERCUTANEOUS CORONARY INTERVENTION IN THE UNITED STATES

Machacz S1, Bonafede MM2, Wade S3, Stephens L1, Hernandez J1
1Abbott Vascular, Santa Clara, CA, USA, 2Truven Health Analytics, Cambridge, MA, USA, 3Wade Outcomes Research and Consulting, Salt Lake City, UT, USA

CV4

3:00 PM - 3:15 PM

OUTCOMES AND HEALTH RESOURCE UTILIZATION AMONG PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF) AT AN ACADEMIC MEDICAL CENTER (AMC) IN THE UNITED STATES

Bress A1, King J1, Singhal M1, Brixner D2, Kielhorn A3, Patel H3, Maya J3, Biskupiak JE1, Munger M1
1University of Utah, Salt Lake City, UT, USA, 2University of Utah, Pharmacotherapy Outcomes Research Center, Program in Personalized Health, Salt Lake City, UT, USA, 3Amgen, Thousand Oaks, CA, USA

2:15 PM - 3:15 PM
Room: Grand Ballroom, Salon K-L (Level 5)
DB: RESEARCH ON DATABASE METHODS STUDIES

DB1

2:15 PM - 2:30 PM

CRITICAL PROBLEMS OF CODING DATA IN HEALTH CARE: OBESITY, SMOKING, AND ALCOHOL USE BY METHOD OF MEASUREMENT

Al Kazzi ES1, Lau B1, Li T2, Schneider EB1, Makary MA1, Hutfless S1
1Johns Hopkins University School of Medicine, Baltimore, MD, USA, 2Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

DB2

2:30 PM - 2:45 PM

A NEW METHOD FOR COUNTING HEMOPHILIA-RELATED BLEEDING EVENTS IN CLAIMS DATA

Shrestha A1, Eldar-Lissai A2, Wu Y1, Batt K3, Krishnan S2, Lakdawalla D4
1Precision Health Economics, Los Angeles, CA, USA, 2Biogen Idec, Cambridge, MA, USA, 3Wake Forest School of Medicine, Winston-Salem, NC, USA, 4University of Southern California, Los Angeles, CA, USA

DB3

2:45 PM - 3:00 PM

THE IMPLICATIONS OF USING A 30-, 60-, OR 90-DAY GAP IN TREATMENT TO SPECIFY LINES OF CARE IN GASTRIC CANCER TREATMENT

Seal B1, Shermock KM2, Asche CV3, Kreilick C1, Xia F1, Kish J4, Zagadailov EA4, Eaddy M4
1Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA, 2The Johns Hopkins Medical Institutions, Baltimore, MD, USA, 3University of Illinois College of Medicine at Peoria, Peoria, IL, USA, 4Xcenda, Palm Harbor, FL, USA

DB4

3:00 PM - 3:15 PM

DEVELOPMENT AND VALIDATION OF ALGORITHMS TO IDENTIFY STATIN INTOLERANCE IN A US ADMINISTRATIVE DATABASE

Foody JM1, Lamerato L2, Dalal M3, Sung JC3, Khan I4, Jhaveri M3, Koren A3, Schulman KL5
1Harvard Medical School, Boston, MA, USA, 2Henry Ford Health System, Detroit, MI, USA, 3Sanofi US, Inc., Bridgewater, NJ, USA, 4Sanofi, Bridgewater, NJ, USA, 5Outcomes Research Solutions, Inc., Bolton, MA, USA

2:15 PM - 3:15 PM
Room: Grand Ballroom, Salon H (Level 5)
HM: HEALTH CARE MANAGEMENT STUDIES

HM1

2:15 PM - 2:30 PM

UTILIZATION OF ANTIDIABETICS AFTER FDA SAFETY ANNOUNCEMENTS

Ding Y1, Gascue L1, Lu Y2, Ning N1, Joyce G1
1University of Southern California, Los Angeles, CA, USA, 2Harbor-UCLA Medical Center, Torrance, CA, USA

HM2

2:30 PM - 2:45 PM

DIFFERENCES IN MASTECTOMY RATES BASED ON HORMONE RECEPTOR STATUS IN EARLY STAGE TUMORS: A SEER DATABASE ANALYSIS

Hinyard L, Schwartz T
Saint Louis University, St. Louis, MO, USA

HM3

2:45 PM - 3:00 PM

A REVIEW OF THE LITERATURE REGARDING BIOSIMILARS: WHAT IS THE EVIDENCE FOR EQUIVALENCE?

Raisch DW1, Chen C1, Tuenter H2, Bennett C3, IJzerman MJ2
1University of New Mexico College of Pharmacy, Albuquerque, NM, USA, 2University of Twente, Enschede, The Netherlands, 3University of South Carolina College of Pharmacy, Columbia, SC, USA

HM4

3:00 PM - 3:15 PM

HOW MUCH EVIDENCE DO WE NEED BEFORE IMPLEMENTING PHARMACOGENOMIC TESTING IN THE CLINIC?

Guzauskas GF, Serbin M, Veenstra DL
University of Washington, Seattle, WA, USA

2:15 PM - 3:15 PM
Room: Grand Ballroom, Salon C, D, E (Level 5)
MA: MEDICATION ADHERENCE STUDIES

MA1

2:15 PM - 2:30 PM

IMPACT OF A PHARMACIST MEDICATION ADHERENCE CONSULTATION PROGRAM ON HEALTH CARE COSTS AND RISK OF HOSPITALIZATION

Wade RL1, Hill JW1, Akinbosoye O2, Jiang Z2, Mu Y2, Sun K1, Karkare S3, Taitel MS2
1IMS Health, Plymouth Meeting, PA, USA, 2Walgreen Co., Deerfield, IL, USA, 3IMS Health, Deerfield, IL, USA

MA2

2:30 PM - 2:45 PM

COST OF NON-ADHERENCE TO MEDICATION IN A POST-MI POPULATION

Garrido E1, Arnold RJ1, Bansilal S2, Castellano JM2, Wei HG3, Freeman A4, Garcia-Alonso F5, Espinosa C6, Lizano I6, Spettell C4, Steinberg G3, Fuster V2
1Icahn School of Medicine at Mount Sinai, New York, NY, USA, 2The Mount Sinai Medical Center, New York, NY, USA, 3Aetna, New York, NY, USA, 4Aetna, Data Science, Hartford, CT, USA, 5Ferrer internacional, Barcelona, Spain, 6Ferrer, Barcelona, Spain

MA3

2:45 PM - 3:00 PM

THE EFFECT OF COST-RELATED MEDICATION NONADHERENCE ON THE DECISION OF TAKING UP MEDICARE PART D AMONG ELDERLY MEDICARE BENEFICIARIES

Han Y, Balkrishnan R
University of Michigan, Ann Arbor, MI, USA

MA4

3:00 PM - 3:15 PM

COMPREHENSIVE ASSESSMENT OF PATIENT ADHERENCE TO DRUG THERAPY: AN EXAMPLE UTILIZING REAL WORLD DATA FOR AN ORAL MULTIPLE SCLEROSIS TREATMENT

Irwin DE1, Cappell KA2, Davis BM2, Wu Y3, Grinspan A4, Gandhi SK3
1Truven Health Analytics, Chapel Hill, NC, USA, 2Truven Health Analytics, Ann Arbor, MI, USA, 3TEVA Pharmaceuticals, Frazer, PA, USA, 4Teva Pharmaceuticals, Weston, FL, USA

2:15 PM - 3:15 PM
Room: Grand Ballroom, Salon I (Level 5)
MD: MEDICAL DEVICE & DIAGNOSTIC RESEARCH STUDIES

MD1

2:15 PM - 2:30 PM

ECONOMIC EVALUATION OF BST-CARGEL AS AN ADJUNCT TO MICROFRACTURE VERSUS MICROFRACTURE ALONE IN KNEE CARTILAGE SURGERY

Frappier J
Data 4 Actions, Blainville, QC, Canada

MD2

2:30 PM - 2:45 PM

COVERAGE LIMITS ON BLOOD GLUCOSE TEST STRIP REIMBURSEMENT FOR DIABETICS IN CANADA: UTILIZATION IMPACT FOR DIABETIC PATIENTS IN THE ONTARIO PUBLIC DRUG PROGRAM (OPDP)

Bosnic N1, Goodfield JM2, Robertson CM2, Zhang Y1
1IMS Brogan, Kanata, ON, Canada, 2IMS Brogan, Mississauga, ON, Canada

MD3

2:45 PM - 3:00 PM

ECONOMIC IMPACT OF CHANGES IN NICU VENTILATION STRATEGIES WITH THE ADVENT OF NEW NONINVASIVE VENTILATION TECHNIQUES: A REVIEW AND PROPOSED ASSESSMENT FRAMEWORK FOR HIGH FLOW THERAPY (HFT) AS A ROUTINE RESPIRATORY SUPPORT PARADIGM

Pietzsch JB1, Garner AM1, McQueen MC2
1Wing Tech Inc., Menlo Park, CA, USA, 2Banner Thunderbird Medical Center, Glendale, AZ, USA

MD4

3:00 PM - 3:15 PM

ECONOMIC VALUE OF IMPROVED ACCURACY FOR SELF-MONITORING OF BLOOD GLUCOSE DEVICES FOR TYPE 1 DIABETES

McQueen RB1, Breton M2, Ott M3, Koa H4, Beamer B4, Campbell JD1
1University of Colorado Anschutz Medical Campus, Denver, CO, USA, 2University of Virginia Health System, Charlottesville, CO, USA, 3Bayer HealthCare, Leverkusen, Germany, 4Bayer HealthCare, Etobicoke, ON, Canada

2:15 PM - 3:15 PM
Room: Grand Ballroom, Salon A, B, F (Level 5)
MO: RESEARCH ON MODELING METHODS STUDIES

MO1

2:15 PM - 2:30 PM

REDUCING AND QUANTIFYING OVER-FITTING IN REGRESSION MODELS

Rigg J, Hankins M
IMS Health, London, UK

MO2

2:30 PM - 2:45 PM

A COMPARISON OF STATE TRANSITION AND DISCRETE EVENT MODELING APPROACHES FOR ANTIPLATELET USE IN THE SECONDARY PREVENTION OF THROMBOTIC EVENTS AFTER MYOCARDIAL INFARCTION (MI)

Ozer-Stillman I1, Whalen JD2, Bash LD3, Du M1, Oguz M1, Singhal PK4, Davies GM4
1Evidera, Lexington, MA, USA, 2Evidera, London, UK, 3Merck and Co., Inc., Rahway, NJ, USA, 4Merck and Co., Inc., North Wales, PA, USA

MO3

2:45 PM - 3:00 PM

DOES THE USE OF EFFICACY OR EFFECTIVENESS EVIDENCE IN COST-EFFECTIVENESS ANALYSES MATTER?

Dilokthornsakul P1, Chaiyakunapruk N2, Campbell JD3
1Center of Pharmaceutical Outcomes Research , Naresuan University, Muang, Phitsanulok, Thailand, 2Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway, Selangor, Malaysia, 3University of Colorado Anschutz Medical Campus, Denver, CO, USA

MO4

3:00 PM - 3:15 PM

EXTRAPOLATING ALL-CAUSE MORTALITY ESTIMATES IN ECONOMIC EVALUATIONS: A SIMULATION ANALYSIS

Pechlivanoglou P1, Abrahamyan L2, Paulden M3, Pham B4, Krahn MD4
1THETA (Toronto Health Economics and Technology Assessment Collaborative), Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3University of Alberta, Edmonton, AB, Canada, 4Toronto Health Economics and Technology Assessment (THETA) Collaborative, Toronto, ON, Canada
3:15 PM - 3:45 PM
BREAK & EXHIBITS VIEWING
3:45 PM - 4:45 PM
RESEARCH PODIUM PRESENTATIONS - SESSION II

3:45 PM - 4:45 PM
Room: Grand Ballroom, Salon A, B, F (Level 5)
CN: CANCER OUTCOMES RESEARCH STUDIES

CN1

3:45 PM - 4:00 PM

THE IMPACT OF CHRONIC CONDITIONS ON THE ECONOMIC BURDEN OF CANCER SURVIVORSHIP IN THE UNITED STATES

Guy G1, Ekwueme D2, Li R1, Rim SH1, Yabroff KR3
1Centers for Disease Control and Prevention, Atlanta, GA, USA, 2Centers for Disease Control and Prevention, Chamblee, GA, USA, 3National Cancer Institute, Rockville, MD, USA

CN2

4:00 PM - 4:15 PM

A COMPARATIVE COST UTILITY ANALYSIS FOR FIRST LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH EGFR EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS

Carlson JJ1, Slejko JF2, Goertz H3, Veenstra DL1
1University of Washington, Seattle, WA, USA, 2University of Maryland, Baltimore, MD, USA, 3Genentech, South San Francisco, CA, USA

CN3

4:15 PM - 4:30 PM

SYNTHESIS OF MULTIPLE TYPES OF SURVIVAL DATA WITHIN A WEIBULL PROPORTIONAL HAZARDS META-ANALYSIS: TREATMENT OUTCOMES IN PATIENTS WITH DOUBLE HIT LYMPHOMA (DHL)

Snedecor SJ1, Howlett C2, Mato A3
1Pharmerit International, Bethesda, MD, USA, 2Rutgers, The State University of New Jersey, Piscataway, NJ, USA, 3University of Pennsylvania, Philadelphia, PA, USA

CN4

4:30 PM - 4:45 PM

REIMBURSEMENT DECISION LANDSCAPE FOR METASTATIC BREAST CANCER THERAPIES: A COMPARISON OF FACTORS LEADING TO FAVORABLE AND UNFAVORABLE RECOMMENDATIONS ACROSS LEADING HTA AGENCIES

Banerjee P, Gupta J, Kumar P, Kapoor A, Mazumder D
Optum Global Solutions, Noida, India

3:45 PM - 4:45 PM
Room: Grand Ballroom, Salon I (Level 5)
CP: CONCEPTUAL PAPERS

CP1

3:45 PM - 4:00 PM

METHODS TO ASSESS THE ASSOCIATION OF PATIENT-REPORTED OUTCOMES AND CLINICAL ENDPOINTS

Odom D, McLeod L, Sherif B, Nelson L
RTI Health Solutions, Research Triangle Park, NC, USA

CP2

4:00 PM - 4:15 PM

INTERVENTIONS FOR ULTRA-RARE DISORDERS (URDS) AND THE LOGIC OF COST EFFECTIVENESS

Schlander M1, Garattini S2, Holm S3, Kolominsky-Rabas P4, Marshall DA5, Nord E6, Persson U7, Postma M8, Richardson J9, Simoens S10, de Sola-Morales O11, Tolley K12, Toumi M13
1University of Heidelberg, Wiesbaden, Germany, 2Mario Negri Institute for Pharmacological Research, Milano, Italy, 3University of Manchester, Manchester, UK, 4Centre for Health Technology Assessment (HTA) and Public Health (IZPH), Friedrich-Alexander-University of Erlangen-Nürnberg; National Leading-Edge Cluster Medical Technologies ‘Medical Valley EMN’, Erlangen, Germany, 5Alberta Bone and Joint Health Institute, Calgary, AB, Canada, 6Norwegian Institute of Public Health, Oslo, Norway, 7The Swedish Institute for Health Economics (IHE), Lund, Sweden, 8University of Groningen, Groningen, The Netherlands, 9Monash University, Clayton, Victoria, Australia, 10KU Leuven, Leuven, Belgium, 11Sabirmedical, Barcelona, Spain, 12Tolley Health Economics Ltd., Buxton, Derbyshire, UK, 13Université Aix Marseilles, Marseilles, France

CP3

4:15 PM - 4:30 PM

LIFE AT A PREMIUM: CONSIDERING AN END-OF-LIFE PREMIUM IN VALUE-BASED REIMBURSEMENT

McCabe C1, Paulden M1, O'Mahony JF2, Edlin R3, Culyer AJ4
1University of Alberta, Edmonton, AB, Canada, 2Trinity College Dublin, Dublin, Ireland, 3University of Auckland, Auckland, New Zealand, 4University of Toronto, Toronto, ON, Canada

CP4

4:30 PM - 4:45 PM

GUIDANCE FOR THE CONDUCT AND REPORTING OF MODELING AND SIMULATION IN THE CONTEXT OF HEALTH TECHNOLOGY ASSESSMENT

Dahabreh I1, Balk E1, Wong JB2, Trikalinos TA1
1Brown University, Providence, RI, USA, 2Tufts Medical Center/Tufts University School of Medicine, Boston, MA, USA

3:45 PM - 4:45 PM
Room: Grand Ballroom, Salon H (Level 5)
CS: RESEARCH ON COST STUDIES METHODS

CS1

3:45 PM - 4:00 PM

US BASED DRUG COST PARAMETER ESTIMATES USING NATIONAL AVERAGE DRUG ACQUISITION COST

Levy JF, Rosenberg MA, Vanness DJ
University of Wisconsin-Madison, Madison, WI, USA

CS2

4:00 PM - 4:15 PM

ECONOMIC MODELLING IN RANDOMIZED CONTROLLED TRIAL (RCT)-BASED ECONOMIC EVALUATIONS: EMPIRICAL EXAMPLES OF ITS EFFECT ON THE PRECISION OF ECONOMIC AND DECISION OUTCOMES

Nam J, Berry C, Henderson R, Briggs A
University of Glasgow, Glasgow, UK

CS3

4:15 PM - 4:30 PM

CURE MODELS: ACCOUNTING FOR CURED PATIENTS IN ECONOMIC EVALUATIONS

Othus M1, Bansal A2, Koepl L1, Wagner S3, Ramsey S1
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 2University of Washington, Seattle, WA, USA, 3Bristol-Myers Squibb, Washington Crossing, PA, USA

CS4

4:30 PM - 4:45 PM

A REVIEW AND UPDATE TO THE GUIDANCE DOCUMENT FOR THE COSTING PROCESS IN THE CANADIAN HEALTH CARE SETTING

Budden AJ1, Lee K1, Jacobs P2
1CADTH, Ottawa, ON, Canada, 2Institute of Health Economics, Edmonton, AB, Canada

3:45 PM - 4:45 PM
Room: Grand Ballroom, Salon C, D, E (Level 5)
HE: HEALTH CARE EXPENDITURE STUDIES

HE1

3:45 PM - 4:00 PM

HEALTH CARE RESOURCE UTILIZATION AMONG MEDICARE BENEFICIARIES WITH COPD: COMPARISON OF HIGH AND LOW UTILIZERS

Xu X, Rao Y, Miyasato G
Trinity Partners, LLC, Waltham, MA, USA

HE2

4:00 PM - 4:15 PM

EXPLAINING THE EXCESS HOME HEALTH CARE USE AND EXPENDITURES AMONG ELDERLY MEDICARE BENEFICIARIES WITH PARKINSON'S DISEASE

Bhattacharjee S1, Metzger A2, Tworek C1, Wei W3, Pan X4, Sambamoorthi U2
1The University of Arizona, Tucson, AZ, USA, 2West Virginia University, Morgantown, WV, USA, 3Sanofi US LLC, Bridgewaters, NJ, USA, 4Evidera LLC, Lexington, MA, USA

HE3

4:15 PM - 4:30 PM

LONG-TERM HEALTH CARE COSTS AMONG ADULTS WITH TYPE 2 DIABETES INITIATING DPP-4 INHIBITORS

Farr AM1, Sheehan J2, Brouillette M1, Smith DM1, Johnston S1, Kalsekar I3
1Truven Health Analytics, Bethesda, MD, USA, 2AstraZeneca, Fort Washington, PA, USA, 3AstraZeneca, Wilmington, DE, USA

HE4

4:30 PM - 4:45 PM

OPTIMIZING CANCER CLINICAL TRIALS RESEARCH INVESTMENT DECISIONS IN THE UNITED STATES: A PROOF OF CONCEPT PORTFOLIO MANAGEMENT EVALUATION

Bennette CS1, Roth JA2, Basu A1, Carlson JJ1, Ramsey S2, Veenstra DL1
1University of Washington, Seattle, WA, USA, 2Fred Hutchinson Cancer Research Center, Seattle, WA, USA

3:45 PM - 4:45 PM
Room: Grand Ballroom, Salon G (Level 5)
HT: HEALTH TECHNOLOGY ASSESSMENT STUDIES

HT1

3:45 PM - 4:00 PM

SYSTEMATIC REVIEW OF COST EFFECTIVENESS OF ULTRA-ORPHAN THERAPIES: LESSON LEARNED FROM PUBLISHED HTAS AND STUDIES

Aggarwal S1, Topaloglu H1, Kumar S2
1NOVEL Health Strategies, Chevy Chase, MD, USA, 2GLOBAL ACCESS Monitor, Bethesda, MD, USA

HT2

4:00 PM - 4:15 PM

APPLICATION OF COST-EFFECTIVENESS LOGIC TO US MANAGED CARE DRUG FORMULARIES: LONG TERM OUTCOMES OF A VALUE-BASED FORMULARY

Yeung K1, Basu A2, Hansen RN1, Watkins J3, Sullivan SD2
1School of Pharmacy, University of Washington, Seattle, WA, USA, 2University of Washington, Seattle, WA, USA, 3Premera Blue Cross, Mountlake Terrace, WA, USA

HT3

4:15 PM - 4:30 PM

ANALYSIS OF NICE DRUG TECHNOLOGY APPRAISALS (2001-SEPTEMBER 2014)

Briceno V, Seoane-Vazquez E
MCPHS University, Boston, MA, USA

HT4

4:30 PM - 4:45 PM

IQWIG EARLY BENEFIT ASSESSMENTS OF TYPE 2 DIABETES THERAPIES

Oehrlein EM, Hanna ML, Perfetto EM
University of Maryland, School of Pharmacy, Baltimore, MD, USA

3:45 PM - 4:45 PM
Room: Grand Ballroom, Salon K-L (Level 5)
PP: PATIENT PREFERENCE STUDIES

PP1

3:45 PM - 4:00 PM

PATIENTS' AND PHYSICIANS' TIME TRADE-OFF PREFERENCES FOR ADVERSE OUTCOMES ASSOCIATED WITH METASTATIC COLORECTAL CANCER TREATMENTS

Morlock R1, Gonzalez JM2, Ogale S1, Sommer N1, Posner J2, Grothey A3
1Genentech, South San Francisco, CA, USA, 2RTI Health Solutions, Research Triangle Park, NC, USA, 3Mayo, Rochester, MN, USA

PP2

4:00 PM - 4:15 PM

PATIENT PREFERENCES FOR FIRST-LINE MAINTENANCE TREATMENTS FOR OVARIAN CANCER

Mansfield CA1, Poulos C1, Hackshaw MD2, Pugh A1, Jobanputra MH2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2GlaxoSmithKline, Philadelphia, PA, USA

PP3

4:15 PM - 4:30 PM

PATIENT VERSUS GENERAL POPULATION PREFERENCES IN ANTICOAGULANT THERAPY

Najafzadeh M, Gagne JJ, Choudhry NK, Polinski J, Avorn JL, Schneeweiss S
Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

PP4

4:30 PM - 4:45 PM

MEASURING TREATMENT PREFERENCES OF PATIENTS DIAGNOSED WITH IDIOPATHIC PULMONARY FIBROSIS USING BEST-WORST SCALING

Camponeschi GF1, Bridges JF2, Danoff SK1, Richardson B1
1Johns Hopkins University, Baltimore, MD, USA, 2John Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
3:45 PM - 7:45 PM
RESEARCH POSTER PRESENTATIONS - SESSION II
5:00 PM - 6:00 PM
WORKSHOPS - SESSION I
Health Policy Development Using Outcomes Research
5:00 PM - 6:00 PM
Room: Grand Ballroom, Salon A, B, F (Level 5)
W1: PATIENT-CENTERED BENEFIT-RISK ANALYSIS: REGULATORY DEVELOPMENTS AND PROSPECTS
Discussion Leaders:

F. Reed Johnson, PhD, Senior Research Scholar, Duke Clinical Research Institute, Duke University, Durham, NC, USA

John F.P. Bridges, PhD, Associate Professor, Department of Health Policy and Management and International Health, John Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

Lou Garrison, PhD, Professor, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA bio

Bennett Levitan, MD, PhD, Senior Director, Benefit-risk Assessment, Epidemiology, Janssen Research & Development, LLC, Titusville, NJ, USA


5:00 PM - 6:00 PM
Room: Grand Ballroom, Salon C, D, E (Level 5)
W2: MAKING BETTER USE OF COMPANY PHARMACOECONOMIC MODELS
Discussion Leaders:

Michael Drummond, MCom, DPhil, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK bio

Laurie Fazio, BS, Vice President, Market Access Technologies, Dymaxium, Inc., Toronto, ON, Canada

John Watkins, PharmD, MPH, BCPS, Formulary Manager, Premera Blue Cross, Mountlake Terrace, WA, USA

H. Keri Yang, PhD, MPH, MS, Director, Center for Observational and Real World Evidence, Merck & Co., Inc., West Point, PA, USA

Use of Real World Data
5:00 PM - 6:00 PM
Room: Grand Ballroom, Salon I (Level 5)
W3: SELECTION BIAS AND COST ALLOCATION IN PATIENTS WITH POLYCHRONIC DISEASE
Discussion Leaders:

Kathy L. Schulman, MS, Managing Director, Outcomes Research Solutions, Inc., Bolton, MA, USA

Lei Liu, PhD, Associate Professor, Preventive Medicine-Biostatistics, Northwestern University, Chicago, MA, USA

Robin Turpin, PhD, Director, Takeda Pharmaceuticals USA, Deerfield, IL, USA


5:00 PM - 6:00 PM
Room: Grand Ballroom, Salon G (Level 5)
W4: IDENTIFYING PATIENTS WITH RARE DISORDERS USING ADMINISTRATIVE DATA
Discussion Leaders:

Daniel C. Malone, PhD, RPh, FAMCP, Professor of Pharmacy, College of Pharmacy and Associate Professor, Mel & Enid Zuckerman College, University of Arizona, Tucson, AZ, USA bio

Wei-Shi Yeh, PhD, Associate Director, Global Market Access, Biogen Idec, Cambridge, MA, USA

Edward P. Armstrong, PharmD, President, Strategic Therapeutics, LLC, Oro Valley, AZ, USA

Eric J. Bell, BS, Principal, One Tall Tree, LLC, Seattle, WA, USA

Clinical Outcomes Research
5:00 PM - 6:00 PM
Room: Grand Ballroom, Salon J (Level 5)
W5: INDIRECT COMPARISONS FOR SINGLE-ARM TRIALS OR TRIALS WITHOUT COMMON COMPARATOR ARMS: WHAT METHODS ARE AVAILABLE, HOW HAVE THEY BEEN USED AND HOW CAN WE EVALUATE RESULTS?
Discussion Leaders:

Elyse Swallow, MA, MPP, Manager, Health Economics and Outcomes Research, Analysis Group, Inc., Boston, MA, USA

James Signorovitch, PhD, Vice President, Health Economics and Outcomes Research, Analysis Group, Inc., Boston, MA, USA

Anupama Kalsekar, MS, Director, World Wide Health Economics and Outcomes Research, Bristol-Myers Squibb, Princeton, NJ, USA

Yong Yuan, PhD, Director, World Wide Health Economics and Outcomes Research, Bristol-Myers Squibb Pharmaceuticals Ltd, Princeton, NJ, USA

Economic Outcomes Research
5:00 PM - 6:00 PM
Room: Grand Ballroom, Salon H (Level 5)
W6: APPLYING DYNAMIC SIMULATION MODELING METHODS IN HEALTH CARE DELIVERY RESEARCH – THE SIMULATE CHECKLIST AND EMERGING GOOD PRACTICES: REPORTS OF THE ISPOR SIMULATION MODELING EMERGING GOOD PRACTICES TASK FORCE
Discussion Leaders:

Deborah A. Marshall, PhD, Canada Research Chair, Health Services and Systems Research & Associate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary, Alberta Bone and Joint Health Institute, Calgary, AB, Canada

Mitchell Higashi, PhD, Chief Economist, GE Healthcare, Barrington, IL, USA

Peter Wong, PhD, MS, MBA, BSC, RPh, Vice President & Chief Performance Improvement Officer, Illinois Divisions and Medical Group, HSHS, Belleville, IL, USA

Kalyan S. Pasupathy, PhD, Faculty, Healthcare Policy & Research, Mayo Clinic, Rochester, MN, USA

Patient-Reported Outcomes & Patient Preference Research
5:00 PM - 6:00 PM
Room: Grand Ballroom, Salon K-L (Level 5)
W7: ASSESSING PERFORMANCE OUTCOME MEASURES FOR REGULATORY REVIEW: CONCEPTUAL AND METHODOLOGICAL CHALLENGES WITH REAL WORLD EXAMPLES
Discussion Leaders:

Rachel Simone Ballinger, PhD, Senior Outcomes Researcher, Patient-Reported Outcomes, ICON, Oxford, UK

Elizabeth Nicki Bush, MHS, Research Scientist, Global Patient Outcomes and Real World Evidence, Eli Lilly, Indianapolis, IN, USA

Ashley Slagle, PhD, Clinical Outcome Assessment Qualification Scientific Coordinator & Study Endpoints Reviewer, U.S. Food and Drug Administration, Silver Spring, MD, USA

Diana Rofail, PhD, CPsychol, Global Head of Patient-Centered Outcomes Research, Neuroscience and Metabolism, Roche Products Limited, Welwyn Garden City, UK

6:00 PM - 7:45 PM
EXHIBITORS' OPEN HOUSE RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION II
6:15 PM - 7:15 PM
ISPOR FORUMS - SESSION I

6:15 PM - 7:15 PM
Room: Grand Ballroom, Salon H (Level 5)
F1: MEASUREMENT OF HEALTH STATE UTILITY VALUES FOR ECONOMIC MODELS IN CLINICAL STUDIES – FINDINGS OF THE GOOD PRACTICES TASK FORCE
Moderator:

Sorrel Wolowacz, PhD, Head, European Health Economics, RTI Health Solutions, Manchester, UK

Speakers:

Andrew Briggs, DPhil, MSc, William R. Lindsay Professor of Health Economics, Health Economics & Health Technology Assessment, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK

Lynda Doward, MRes, European Head, Patient-Reported Outcomes, RTI Health Solutions, Manchester, UK

Andrew Lloyd, PhD, Scientific Advisor, Patient Reported Outcomes, ICON plc., Oxford, UK


6:15 PM - 7:15 PM
Room: Grand Ballroom, Salon C, D, E (Level 5)
F2: CLINICAL OUTCOME ASSESSMENTS (COAS): A CONCEPTUAL FOUNDATION AND DEVELOPING AND EVALUATING CLINICIAN-REPORTED OUTCOME (CLINRO) INSTRUMENTS TO ASSESS TREATMENT BENEFIT: EMERGING GOOD PRACTICES
Moderator:

John H. Powers, MD, FACP, FIDSA, Associate Clinical Professor of Medicine, George Washington University School of Medicine, Washington, DC, USA

Speakers:

Laurie B. Burke, RPh, MPH, Founder, Lora Group, LLC, Royal Oak, MD, USA and Former Director, Study Endpoints and Labeling Development, ONDIO, CDER, U.S. Food & Drug Administration, Silver Spring, MD, USA

Donald Patrick, PhD, MSPH, Professor, Department of Health Services & Director, Seattle Quality of Life Group & Biobehavioral Cancer Training Program, University of Washington, Seattle, WA, USA

Stefan Cano, PhD, CPsychol, AFBPsS, Co-Founder and Chief Science Officer, Modus Outcomes, Stotfold, UK

Patrick Marquis, MD, MBA, President, Twolegs Consulting, Newton, MA, USA


6:15 PM - 7:15 PM
Room: Grand Ballroom, Salon A, B, F (Level 5)
F3: PATIENT ENGAGEMENT IN HEALTH ECONOMIC AND OUTCOMES RESEARCH: CURRENT AND FUTURE ISPOR INITIATIVES
Moderator:

Todd Berner, MD, XX, XX, XX, Northbook, IL, USA

Speakers:

Amie Scott, MPH, Business Health Research Analyst, SEAS Capital Partners, LLC, Plymouth, MI, USA

Don Husereau, BScPharm, MSc, Senior Associate, Institute of Health Economics & Adjunct Professor, Epidemiology and Community Medicine, University of Ottawa, Ottawa, ON, Canada

Emil Chiauzzi, PhD, Research Director, PatientsLikeMe, Cambridge, MA, USA

Rob Camp, Communications Manager, EUPATI, Barcelona, Spain


6:15 PM - 7:15 PM
Room: Grand Ballroom, Salon K-L (Level 5)
F4: FROM COST-EFFECTIVENESS TO EQUITY: CHALLENGES FACING HEALTH CARE SYSTEMS IN LATIN AMERICA
Moderator:

Hector Castro, MD, MS, PhD, Chief Executive Officer, Health Technology Assessment Institute of Colombia (IETS), Bogota, Colombia

Speakers:

Marcelo Fonseca, MD, MSc, Professor, Assistant Physician, Federal University of São Paulo, São Paulo, Brazil

Rosa Maria Galindo Suarez, MHA, Deputy General Director of Prioritization, General Health Council, Mexico City, Mexico

Manuel Antonio Espinoza, MD, MSc, PhD, Chair-elect, ISPOR Latin America Consortium Executive Committee, Professor of Health Economics and Chief Unit of Health Technology Assessment, Faculty of Medicine, Santiago, Chile

Diego Rosselli, MD, MEd, MSc, Associate professor, Clinical Epidemiology and Biostatistics Department, Pontificia Universidad Javeriana, Bogota, Colombia


6:15 PM - 7:15 PM
Room: Grand Ballroom, Salon G (Level 5)
F5: INTEGRATING BIG DATA INTO REAL WORLD PRACTICE
Moderator:

Zeba M. Khan, RPh, PhD, Vice President, Celgene Corporation, Summit, NJ, USA

Speakers:

William H. Crown, PhD, Chief Scientific Officer, Optum Labs, Cambridge, MA, USA

Marc Berger, MD, Vice President, Real World Data and Analytic, Pfizer, Inc., New York, NY, USA


6:15 PM - 7:15 PM
Room: Grand Ballroom, Salon I (Level 5)
F6: SYNCING INFORMATION CHAINS WITH HEALTH SYSTEMS DEVELOPMENT FOR BETTER OUTCOMES
Moderator:

Gabriela Tannus, MBA, MSc, Owner & Health Economics Director, Axia.Bio Consulting, Sao Paolo, Brazil

Speakers:

Vitaly V. Omelianovskiy, MD, PhD, Director, Centre of HTA, Moscow, Russia

Jitendar Sharma, PhD, Head, Division of Healthcare Technology, National Health Systems Resource Center, Ministry of Health & Family Welfare, New Delhi, India

Kun Zhao, MD, PhD, Professor & Director, Division of Health Technology Assessment, China National Health Development, Research Center, National Health and Family Planning Commission (NHFPC), Beijing, China

Nikash Bagirathi, BSc, Bmed (Hons), Managed Healthcare Manager, Medtronic, Johannesburg, South Africa


6:15 PM - 7:15 PM
Room: Grand Ballroom, Salon J (Level 5)
F7: BUDGET IMPACT ANALYSIS OF EPIDEMIC DISEASES ACROSS AFRICA
Moderator:

Anthony Waka Udezi, PhD, President, ISPOR Nigeria Chapter, Associate Professor & Assistant Dean, Department of Clinical Pharmacy, University of Benin, Benin City, Nigeria

Speakers:

Peter Agyei-Baffour, PhD, President, ISPOR Ghana Chapter and Lecturer & Researcher, Department of Community Health, School of Medical Sciences, Kwame Nkrumah University of Sciences and Technology (KNUST), Kumasi, Ghana

Paul La Cock, MPharm, Consultant, inScisive, Cape Town, South Africa

Abdalla Aly, BPharm, PhD, Associate Scientist, Health Economics and Outcomes, Pharmerit International, Bethesda, MD, USA

6:45 PM - 7:45 PM
POSTER AUTHOR DISCUSSION HOUR - SESSION II
7:15 PM - 8:45 PM
ISPOR LATIN AMERICA CONSORTIUM RECEPTION
Room: JW's Mezzanine (Off Main Lobby)

Meet, network with, and hear from key thought leaders and colleagues from Latin America! This reception is open to all meeting attendees interested in the ISPOR Latin America Consortium. 

7:15 PM - 8:45 PM
ISPOR ASIA CONSORTIUM WELCOME RECEPTION
Room: Liberty Ballroom A (Level 3)
A great opportunity to meet and network with key opinion leaders and colleagues from the Asia-Pacific region! All attendees interested in the ISPOR Asia Consortium are welcome to attend.
7:15 PM - 8:45 PM
ISPOR ARABIC NETWORK AND AFRICA NETWORK WELCOME RECEPTION
Room: Liberty Ballroom B (Level 3)
Join ISPOR colleagues from Western Asia and Africa in this networking opportunity. Come and meet regional experts in health economics, learn about the Networks activities and find out how to get involved!
Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.